EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NextCure's enterprise value is $-45.47 Mil.
NextCure's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-62.81 Mil. Therefore, NextCure's EV-to-EBITDA for today is 0.72.
The historical rank and industry rank for NextCure's EV-to-EBITDA or its related term are showing as below:
NXTC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.63 Med: 2.9 Max: 6.63
Current: 0.72
During the past 7 years, the highest EV-to-EBITDA of NextCure was 6.63. The lowest was -56.63. And the median was 2.90.
NXTC's EV-to-EBITDA is ranked better than 73.41% of 455
companies
in the Biotechnology industry
Industry Median: 10.21
vs NXTC: 0.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-15), NextCure's stock price is $1.59.
NextCure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.280. Therefore, NextCure's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
NextCure EV-to-EBITDA Historical Data
The historical data trend for NextCure's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NextCure's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NextCure's EV-to-EBITDA falls into.
NextCure EV-to-EBITDA Calculation
NextCure's EV-to-EBITDA for today is calculated as:
NextCure's current Enterprise Value is $-45.47 Mil.
NextCure's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (NAS:NXTC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NextCure's share price for today is $1.59.
NextCure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of NextCure's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NXTC has been successfully added to your 